The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MPN 2026 | Recommendations for managing patients with MPNs who develop interferon resistance
Marta Sobas, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, shares insights into managing patients with myeloproliferative neoplasms (MPNs) who develop interferon resistance, highlighting that molecular responses can take time and treatment should not be stopped prematurely. Dr Sobas also outlines the potential benefit of combination approaches, such as with JAK inhibitors, and emphasizes the influence of drug interactions on treatment response. This interview took place at the ESH 11th Translational Research Conference on Myeloproliferative Neoplasms (ESH MPN 2026) in Estoril, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
